Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other Non-Current Liabilities (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Other Non-Current Liabilities for 16 consecutive years, with $701000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 9.2% to $701000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $701000.0 through Dec 2025, down 9.2% year-over-year, with the annual reading at $701000.0 for FY2025, 9.2% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $701000.0 at Anika Therapeutics, down from $761000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $16.9 million in Q2 2021, with the low at $398000.0 in Q4 2022.
  • Average Other Non-Current Liabilities over 5 years is $1.7 million, with a median of $684000.0 recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities surged 1904.74% in 2021, then crashed 96.53% in 2022.
  • Over 5 years, Other Non-Current Liabilities stood at $1.3 million in 2021, then plummeted by 68.36% to $398000.0 in 2022, then rose by 1.51% to $404000.0 in 2023, then soared by 91.09% to $772000.0 in 2024, then dropped by 9.2% to $701000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $701000.0, $761000.0, and $756000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.